Logo image of PHIO

PHIO PHARMACEUTICALS CORP (PHIO) Stock Fundamental Analysis

NASDAQ:PHIO - Nasdaq - US71880W5013 - Common Stock

2.29  -0.19 (-7.66%)

Premarket: 2.23 -0.06 (-2.62%)

Fundamental Rating

3

We assign a fundamental rating of 3 out of 10 to PHIO. PHIO was compared to 572 industry peers in the Biotechnology industry. No worries on liquidiy or solvency for PHIO as it has an excellent financial health rating, but there are worries on the profitability. PHIO has a valuation in line with the averages, but on the other hand it scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year PHIO has reported negative net income.
In the past year PHIO has reported a negative cash flow from operations.
PHIO had negative earnings in each of the past 5 years.
PHIO had a negative operating cash flow in each of the past 5 years.
PHIO Yearly Net Income VS EBIT VS OCF VS FCFPHIO Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 -2M -4M -6M -8M -10M

1.2 Ratios

With a Return On Assets value of -126.50%, PHIO is not doing good in the industry: 81.42% of the companies in the same industry are doing better.
With a Return On Equity value of -150.00%, PHIO is not doing good in the industry: 63.89% of the companies in the same industry are doing better.
Industry RankSector Rank
ROA -126.5%
ROE -150%
ROIC N/A
ROA(3y)-86.01%
ROA(5y)-84.94%
ROE(3y)-102.19%
ROE(5y)-105.8%
ROIC(3y)N/A
ROIC(5y)N/A
PHIO Yearly ROA, ROE, ROICPHIO Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 -200 -400 -600

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for PHIO so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
PHIO Yearly Profit, Operating, Gross MarginsPHIO Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 -20K -40K -60K

More info and screens

7

2. Health

2.1 Basic Checks

PHIO has less shares outstanding than it did 1 year ago.
PHIO has more shares outstanding than it did 5 years ago.
There is no outstanding debt for PHIO. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
PHIO Yearly Shares OutstandingPHIO Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 200K 400K 600K 800K 1M
PHIO Yearly Total Debt VS Total AssetsPHIO Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 5M 10M 15M 20M 25M

2.2 Solvency

PHIO has an Altman-Z score of -35.16. This is a bad value and indicates that PHIO is not financially healthy and even has some risk of bankruptcy.
PHIO has a worse Altman-Z score (-35.16) than 92.39% of its industry peers.
PHIO has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -35.16
ROIC/WACCN/A
WACCN/A
PHIO Yearly LT Debt VS Equity VS FCFPHIO Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 10M -10M 20M

2.3 Liquidity

A Current Ratio of 6.38 indicates that PHIO has no problem at all paying its short term obligations.
PHIO has a better Current ratio (6.38) than 64.07% of its industry peers.
PHIO has a Quick Ratio of 6.38. This indicates that PHIO is financially healthy and has no problem in meeting its short term obligations.
With a decent Quick ratio value of 6.38, PHIO is doing good in the industry, outperforming 64.25% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 6.38
Quick Ratio 6.38
PHIO Yearly Current Assets VS Current LiabilitesPHIO Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 5M 10M 15M 20M

More info and screens

1

3. Growth

3.1 Past

The Earnings Per Share has grown by an nice 12.83% over the past year.
EPS 1Y (TTM)12.83%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%84.99%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

PHIO is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 61.36% yearly.
PHIO is expected to show a decrease in Revenue. In the coming years, the Revenue will decrease by 0.00% yearly.
EPS Next Y70.93%
EPS Next 2Y61.36%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2Y0%
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

PHIO Yearly Revenue VS EstimatesPHIO Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 20M 40M 60M
PHIO Yearly EPS VS EstimatesPHIO Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -100K -200K -300K -400K -500K

More info and screens

4

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for PHIO. In the last year negative earnings were reported.
A Price/Forward Earnings ratio of 0.07 indicates a rather cheap valuation of PHIO.
Compared to the rest of the industry, the Price/Forward Earnings ratio of PHIO indicates a rather cheap valuation: PHIO is cheaper than 99.82% of the companies listed in the same industry.
When comparing the Price/Forward Earnings ratio of PHIO to the average of the S&P500 Index (24.37), we can say PHIO is valued rather cheaply.
Industry RankSector Rank
PE N/A
Fwd PE 0.07
PHIO Price Earnings VS Forward Price EarningsPHIO Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
PHIO Per share dataPHIO EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 10 -10 20 30

4.3 Compensation for Growth

The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
A more expensive valuation may be justified as PHIO's earnings are expected to grow with 61.36% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y61.36%
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

No dividends for PHIO!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

PHIO PHARMACEUTICALS CORP

NASDAQ:PHIO (1/22/2025, 8:00:00 PM)

Premarket: 2.23 -0.06 (-2.62%)

2.29

-0.19 (-7.66%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-07 2024-11-07/dmh
Earnings (Next)N/A N/A
Inst Owners2.56%
Inst Owner Change0%
Ins Owners6.03%
Ins Owner Change8.79%
Market Cap3.96M
Analysts82.86
Price Target36.72 (1503.49%)
Short Float %3.97%
Short Ratio0.01
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)43.11%
Min EPS beat(2)22.68%
Max EPS beat(2)63.53%
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 0.07
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 0.8
P/tB 0.8
EV/EBITDA N/A
EPS(TTM)-13.28
EYN/A
EPS(NY)34.7
Fwd EY1515.3%
FCF(TTM)-4.69
FCFYN/A
OCF(TTM)-4.69
OCFYN/A
SpS0
BVpS2.86
TBVpS2.86
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -126.5%
ROE -150%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-86.01%
ROA(5y)-84.94%
ROE(3y)-102.19%
ROE(5y)-105.8%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 0%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 6.38
Quick Ratio 6.38
Altman-Z -35.16
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)80.95%
Cap/Depr(5y)74.29%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)12.83%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%84.99%
EPS Next Y70.93%
EPS Next 2Y61.36%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2Y0%
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y35.78%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y32.46%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y31.78%
OCF growth 3YN/A
OCF growth 5YN/A